論文・総説 - 玉村　啓和

141. Hiroshi Tsutsumi, Hirokazu Tamamura & Nobutaka Fujii. Inhibitors of the Chemokine Receptor CXCR4. Chemotherapy of AIDS, Metastatic Cancer, Leukemia and Rheumatoid Arthritis. Lett. Drug Design Discovery. 2007; 4 20-26.

142. Hirokazu Tamamura, Tomohiro Tanaka, Hiroshi Tsutsumi, Koji Nemoto, Satoko Mizokami, Nami Ohashi, Shinya Oishi & Nobutaka Fujii. Versatile Use of Acid-catalyzed Ring-opening of β-Aziridinyl-α,β-enoates to Stereoselective Synthesis of Peptidomimetics. Tetrahedron. 2007; 63 9243-9254.

143. Tsutsumi H, Tanaka T, Ohashi N, Masuno H, Tamamura H, Hiramatsu K, Araki T, Ueda S, Oishi S, Fujii N. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers. 2007; 88 (2): 279-289. ( PubMed, DOI )

144. Tamamura H, Tsutsumi H, Masuno H, Fujii N. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr Med Chem. 2007; 14 (1): 93-102. ( PubMed )

145. Tamamura H, Tsutsumi H, Fujii N. The chemokine receptor CXCR4 as a therapeutic target for several diseases. Mini Rev Med Chem. 2006.09; 6 (9): 989-995. ( PubMed )

146. Tamamura H, Ojida A, Ogawa T, Tsutsumi H, Masuno H, Nakashima H, Yamamoto N, Hamachi I, Fujii N. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J Med Chem. 2006.06; 49 (11): 3412-3415. ( PubMed, DOI )

147. Tamamura H, Tsutsumi H, Masuno H, Mizokami S, Hiramatsu K, Wang Z, Trent JO, Nakashima H, Yamamoto N, Peiper SC, Fujii N. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Org Biomol Chem. 2006.06; 4 (12): 2354-2357. ( PubMed, DOI )

148. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, Iida Y, Doi R, Fujii N, Saji H. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006.05; 33 (4): 489-494. ( PubMed, DOI )

149. Niida A, Tanigaki H, Inokuchi E, Sasaki Y, Oishi S, Ohno H, Tamamura H, Wang Z, Peiper SC, Kitaura K, Otaka A, Fujii N. Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-SN2' reactions and their use in the preparation of low-molecule CXCR4 antagonists. J Org Chem. 2006.05; 71 (10): 3942-3951. ( PubMed, DOI )

150. Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica. 2006.05; 91 (5): 605-612. ( PubMed )

151. Kasyanov A, Tamamura H, Fujii N, Xiong H. HIV-1 gp120 enhances giant depolarizing potentials via chemokine receptor CXCR4 in neonatal rat hippocampus. Eur J Neurosci. 2006.03; 23 (5): 1120-1128. ( PubMed, DOI )

152. Niida A, Wang Z, Tomita K, Oishi S, Tamamura H, Otaka A, Navenot JM, Broach JR, Peiper SC, Fujii N. Design and synthesis of downsized metastin (45-54) analogs with maintenance of high GPR54 agonistic activity. Bioorg Med Chem Lett. 2006.01; 16 (1): 134-137. ( PubMed, DOI )

153. Tamamura H, Tsutsumi H. Specific probes for chemokine receptors. Chem Biol. 2006.01; 13 (1): 8-10. ( PubMed, DOI )

154. Shinya Oishi, Kazuhide Miyamoto, Ayumu Niida, Mikio Yamamoto, Keiichi Ajito, Hirokazu Tamamura, Akira Otaka, Yoshihiro Kuroda, Akira Asai & Nobutaka Fujii. Application of Tri- and Tetrasubstituted Alkene Dipeptide Mimetics to Conformational Studies of Cyclic RGD Peptides. Tetrahedron. 2006; 62 1416-1424.

155. Hirokazu Tamamura & Hiroshi Tsutsumi. Specific Probes for Chemokine Receptors Chem. Biol.. 2006; 13 8-10.

156. Tamamura H, Esaka A, Ogawa T, Araki T, Ueda S, Wang Z, Trent JO, Tsutsumi H, Masuno H, Nakashima H, Yamamoto N, Peiper SC, Otaka A, Fujii N. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org Biomol Chem. 2005.12; 3 (24): 4392-4394. ( PubMed, DOI )

157. Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets. 2005.12; 9 (6): 1267-1282. ( PubMed, DOI )

158. Ueda S, Fujita M, Tamamura H, Fujii N, Otaka A. Photolabile protection for one-pot sequential native chemical ligation. Chembiochem. 2005.11; 6 (11): 1983-1986. ( PubMed, DOI )

159. Tamamura H, Otaka A, Fujii N. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides. Curr HIV Res. 2005.10; 3 (4): 289-301. ( PubMed )

160. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005.09; 106 (5): 1824-1830. ( PubMed, DOI )